Fig. 6From: Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trialRelationship between baseline SABA use and treatment difference (UMEC/VI vs SAL). CI confidence interval, E-RS Evaluating Respiratory Symptoms: COPD, FEV1 forced expiratory volume in 1 s, LS least squares, SABA short-acting β2-agonist, SAC-TDI self-administered computerised Transition Dyspnoea Index, SAL salmeterol, UMEC umeclidinium, VI vilanterolBack to article page